분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2011-03-23 11:27:23 , Hit : 2352
 Gene therapy offers hope for Parkinson's disease

Published online 17 March 2011 | Nature | doi:10.1038/news.2011.167

Small trial improves patients' symptoms.

Ewen Callaway

An experimental gene-therapy treatment for Parkinson's disease has eased the movement problems of a small number of patients and raised no major safety concerns. The study, reported in The Lancet Neurology1, is the first double-blind clinical trial to show a benefit of gene therapy to patients with the neurodegenerative condition.

Parkinson's disease is characterized by tremors, slowness and cognitive problems, and is caused by the death of neurons in brain circuits that makes dopamine. The effects cascade through interconnected brain regions involved in movement, with some areas becoming overactive.

Many patients are treated with the drug levadopa (L-DOPA), a chemical precursor of dopamine, and regain control of their movements. Over time, however, patients become less sensitive to L-DOPA and burdened by its side effects, which include psychological and physical problems.

Long-term fix
Gene therapy could offer a longer-lasting solution, says Andrew Feigin, a neurologist at the Feinstein Institute for Medical Research in Manhasset, New York, who led the trial along with Michael Kaplitt, at Weill Cornell Medical College in New York and Matthew During, at Ohio State University in Columbus. This involved 45 patients aged between 30 and 75 years old, and was funded by Neurologix of Fort Lee, New Jersey, which holds the patent for the therapy.

Half of the patients received an infusion of a virus engineered to deliver a gene called glutamic acid decarboxylase (GAD) into a brain centre that is overactive in Parkinson's disease — the subthalamic nucleus. GAD encodes a neurotransmitter called GABA, which quiets neurons in this area. Another treatment for Parkinson's, deep brain stimulation (DBS), uses electricity to silence neurons in the same region.

The remaining patients underwent brain surgery, but did not receive the gene therapy.

Six months after these surgeries, Feigin's team measured improvements in both sets of patients using a standardized assessment of Parkinson's disease that looks at factors such as gait, posture, and hand and finger movements. Patients who had received the gene therapy exhibited a 23.1% improvement on this scale, compared with a 12.7% boost for patients who had undergone the placebo surgery. However, patients given the gene therapy did not, as a whole, see any more quality-of-life benefits than the other group.

Feigin's team excluded six patients who may not have received the gene therapy because of problems in its delivery. He says that this is justifiable in a small trial intended to test whether or not a treatment works. "If you included people who didn't get the therapy it could easily wash out the benefit you might see," he says.

In safe hands
One patient who received the gene therapy required treatment for a bowel obstruction 4 months after surgery, but Feigin says this was not related to the therapy.

"I'm very excited to see that it's safe," says Stéphane Palfi, a neurosurgeon at Henri Mondor Hospital in Creteil, France who was not involved in the trial.

However, he notes that DBS typically offers much more benefit to patients with Parkinson's disease. And, he adds, unlike gene therapy, DBS can be tuned up or down depending on a patient's current condition.

Despite this, Palfi remains enthusiastic that gene therapy could provide another tool with which to manage Parkinson's disease. He is involved in an early-stage safety trial for delivering genes involved in making dopamine to the brains of patients with Parkinson's disease. Palfi says that, so far, nine people have received the treatment.

Other scientists are testing gene therapies that prevent neuron from dying in patients with Parkinson's disease.

Marc Panoff, chief financial officer at Neurologix, says that the company will seek permission from the US Food and Drug Administration later this year to conduct a larger clinical trial.

References
LeWitt, P. A. et al. Lancet Neurol. doi:10.1016/S1474-4422(11)70039-4 (2011).







1067   Foamy 바이러스 벡터를 이용한 유전자 치료  이성욱 2008/02/12 5778
1066   Foot-and-mouth culls could be cut  이성욱 2011/05/11 3156
1065   Former Reginans changing the future of HIV  이성욱 2011/12/28 2256
1064   Fragile X syndrome: Trigger for most common form of intellectual disability and autism uncovered  이성욱 2014/03/05 1770
1063   Frances H. Arnold, George P. Smith, and Gregory P. Winter share 2018 Nobel Prize in Chemistry  이성욱 2018/10/04 358
1062   Friends connect on a genetic level  이성욱 2011/01/24 2262
1061   From Startups to Moguls] CRISPR 유전자가위 없이 편집한다? Homology Medicines  이성욱 2017/09/11 606
1060   Gene Editing Treats Blood Disease  이성욱 2011/07/16 3017
1059   Gene Study Based on RNA Interference May Lead to New Liver Cancer Therapies  이성욱 2017/08/14 810
1058   Gene Therapy Allows Beethoven Mouse to Hear  이성욱 2015/07/10 875
1057   Gene Therapy Appears to Help Patient With Anemia  이성욱 2010/09/17 2908
1056   Gene therapy drug approval granted to GSK  이성욱 2016/05/30 935
1055   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 333
1054   Gene Therapy for Controlling HIV Shows Early Promise  이성욱 2014/03/08 1600
1053   Gene Therapy for Immune Disorder Lasts Nine Years, Two New Studies Show  이성욱 2011/08/25 2479
1052   Gene Therapy May Thwart HIV  이성욱 2011/09/23 2056
  Gene therapy offers hope for Parkinson's disease  이성욱 2011/03/23 2352
1050   Gene Therapy Shows Promise Against Age-Related Macular Degeneration  이성욱 2011/05/04 2542
1049   Gene Therapy Shows Promise as Hemophilia Treatment in Animal Studies  이성욱 2011/11/10 2435
1048   Gene therapy trial on hold  이성욱 2007/08/07 4978

[이전 10개] [1].. 11 [12][13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN